THE EFFECT OF ARTESUNATE ON BLEOMYCIN-INDUCED PULMONARY FIBROSIS

Area of Science:

• Pulmonary Medicine
• Pharmacology
• Toxicology

Background:

• Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with no cure.
• Current treatments offer limited efficacy, necessitating research into novel therapeutic agents.

Purpose of the Study:

• To investigate the therapeutic effects of artesunate on fibrosis, pulmonary hypertension, and inflammation in a bleomycin-induced rat model of IPF.
• To evaluate artesunate's impact on exercise capacity, right ventricular hypertrophy, and pulmonary arteriolar remodeling.

Main Methods:

• Male Wistar albino rats were divided into four groups: control, artesunate-only, bleomycin-induced IPF, and bleomycin + artesunate.
• Bleomycin was administered to induce pulmonary fibrosis, followed by artesunate treatment (30 mg/kg/day) or saline for 21 days.
• Exercise capacity, right ventricular hypertrophy (RVH), pulmonary arteriolar wall thickness, fibrosis, and inflammatory markers were assessed.

Main Results:

• Artesunate treatment in bleomycin-induced IPF rats significantly reduced RVH (0.37 ± 0.03 vs. 0.44 ± 0.02) and pulmonary arteriolar wall thickness (p<0.001).
• Significant improvements were observed in fibrosis and inflammatory changes in the bleomycin + artesunate group (p<0.001).
• While exercise capacity showed intergroup differences (p=0.001), no significant difference was found between bleomycin and bleomycin + artesunate groups (p=0.95).

Conclusions:

• Artesunate demonstrates therapeutic potential by ameliorating fibrosis, inflammation, RVH, and pulmonary arteriolar thickening in a rat model of bleomycin-induced pulmonary fibrosis.
• Further research is warranted to explore artesunate's efficacy as a treatment for IPF.
• Artesunate may offer a novel therapeutic strategy for managing key pathological features of IPF.